BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Lowered by Royal Bank Of Canada

by · The Markets Daily

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating in a research note issued on Thursday, Marketbeat reports. They currently have a $11.00 price target on the biotechnology company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 24.86% from the stock’s previous close.

Several other equities analysts have also issued reports on BCRX. Cantor Fitzgerald boosted their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 29th. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Wedbush reduced their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 27th. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $20.40.

View Our Latest Stock Analysis on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Stock Down 2.8%

Shares of NASDAQ BCRX opened at $8.81 on Thursday. The company has a market capitalization of $2.25 billion, a PE ratio of -5.87 and a beta of 0.57. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.22. The firm has a fifty day simple moving average of $9.72 and a 200 day simple moving average of $9.23.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business’s revenue was up 33.6% compared to the same quarter last year. During the same period last year, the business posted $0.15 EPS. As a group, equities analysts expect that BioCryst Pharmaceuticals will post -2.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Royal Bank of Canada grew its position in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares during the period. Cetera Investment Advisers raised its holdings in BioCryst Pharmaceuticals by 13.8% during the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after buying an additional 1,494 shares during the last quarter. Captrust Financial Advisors lifted its stake in shares of BioCryst Pharmaceuticals by 7.4% in the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 1,527 shares in the last quarter. Legato Capital Management LLC lifted its stake in shares of BioCryst Pharmaceuticals by 10.0% in the fourth quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 2,172 shares in the last quarter. Finally, Creative Planning grew its holdings in shares of BioCryst Pharmaceuticals by 2.6% during the third quarter. Creative Planning now owns 88,477 shares of the biotechnology company’s stock valued at $672,000 after buying an additional 2,280 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

(Get Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

Read More